Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses

• US 7,285,287 B2
• Filed: 09/15/2003
• Issued: 10/23/2007
• Est. Priority Date: 11/14/2002
• Status: Expired due to Fees

• Current Assignee: Synecor LLC
• Original Assignee: Synecor LLC
• Inventors: Williams, Michael S., DeSimone, Joseph M.
• Primary Examiner(s): Levy; Neil S.
• Application Number:
  US10/662,621
• Publication Number:
  US 20040098120A1
• Time in Patent Office: 1,499 Days
• Field of Search: 424/405, 424/406, 424423-428, 424/430, 424484-488, 424/700, 424/433, 623 111- 154, 623/901, 264/88
• US Class Current: 424/423
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials

Abstract

Methods of producing biocompatible intraluminal prostheses are provided and include immersing polymeric material of an intraluminal prosthesis in a densified carbon dioxide composition under controlled conditions such that toxic materials are absorbed by the densified carbon dioxide composition.

Claims

1. A method of producing a biocompatible stent for in vivo use, comprising:

providing a stent having a portion thereof formed from polymeric material selected from the group consisting of polylactic acid-polyethylene glycol block copolymer, poly(ethyleneoxide)-poly(butylenetetraphthalate), poly(lactic acid-co-lysine), a poly(L-lactic acid) copolymer and a poly(ε

-caprolactone) copolymer, wherein the polymeric material contains one or more toxic materials;

immersing the polymeric material in a densified carbon dioxide composition such that the toxic materials are absorbed by the densified carbon dioxide composition, wherein pressure and/or temperature of the densified carbon dioxide composition is adjusted to selectively absorb toxic materials from the polymeric material;

removing the densified carbon dioxide composition containing the toxic materials from the polymeric material;

lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and

removing the separated toxic materials, such that the stent is suitable for in vivo use.

2. A method of producing a biocompatible stent for in vivo use, comprising:

providing a stent having a portion thereof formed from polymeric material selected from the group consisting of;

poly(lactic acid), poly(L-lactic acid), poly(D,L-lactic acid), and a copolymer of poly(lactic acid), poly(L-lactic acid), and/or poly(D,L-lactic acid), wherein the polymeric material contains one or more toxic materials;

immersing the polymeric material in a densified carbon dioxide composition such that the toxic materials are absorbed by the densified carbon dioxide composition, wherein pressure and/or temperature of the densified carbon dioxide composition is adjusted to selectively absorb toxic materials from the polymeric material;

removing the densified carbon dioxide composition containing the toxic materials from the polymeric material;

lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and

removing the separated toxic materials, such that the stent is suitable for in vivo use.

3. The method of claim 2, wherein the one or more toxic materials are selected from the group consisting of organic solvents (polar or non-polar), unpolymerized monomers, polymerization catalysts, oligomers, and polymerization initiators.

4. The method of claim 2, wherein the densified carbon dioxide composition is a liquid composition, and wherein the immersing and removing steps are carried out in an enclosed chamber.

5. The method of claim 2, wherein the step of lowering the density comprises reducing pressure and/or increasing temperature of the densified carbon dioxide composition.

6. The method of claim 2, wherein carbon dioxide in the densified carbon dioxide composition is present in a supercritical state.

7. The method of claim 2, wherein the carbon dioxide contains one or more of a co-solvent, a surfactant, and a co-surfactant.

8. The method of claim 2, wherein the polymeric material is a coating on one or more portions of the stent.

9. A method of producing a biocompatible stent for in vivo use, comprising:

providing a stent having a portion thereof formed from polymeric material selected from the group consisting of;

poly(glycolic acid), poly(D-lactic-co-glycolic acid), poly(L-lactic-co-glycolic acid), poly (D,L-lactic-co-glycolic acid), and a copolymer of poly(glycolic acid), poly(D-lactic-co-glycolic acid), poly(L-lactic-co-glycolic acid), or poly (D,L-lactic-co-glycolic acid), wherein the polymeric material contains one or more toxic materials;

immersing the polymeric material in a densified carbon dioxide composition such that the toxic materials are absorbed by the densified carbon dioxide composition, wherein pressure and/or temperature of the densified carbon dioxide composition is adjusted to selectively absorb toxic materials from the polymeric material;

removing the densified carbon dioxide composition containing the toxic materials from the polymeric material;

lowering the density of the removed densified carbon dioxide composition such that the toxic materials entrained therein become separated therefrom; and

removing the separated toxic materials, such that the stent is suitable for in vivo use.

10. The method of claim 9, wherein the one or more toxic materials are selected from the group consisting of organic solvents (polar or non-polar), unpolymerized monomers, polymerization catalysts, oligomers, and polymerization initiators.

11. The method of claim 9, wherein the densified carbon dioxide composition is a liquid composition, and wherein the immersing and removing steps are carried out in an enclosed chamber.

12. The method of claim 9, wherein the step of lowering the density comprises reducing pressure and/or increasing temperature of the densified carbon dioxide composition.

13. The method of claim 9, wherein carbon dioxide in the densified carbon dioxide composition is present in a supercritical state.

14. The method of claim 9, wherein the carbon dioxide contains one or more of a co-solvent, a surfactant, and a co-surfactant.

15. The method of claim 9, wherein the polymeric material is a coating on one or more portions of the stent.